- Trials with a EudraCT protocol (78)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
78 result(s) found for: non-hodgkins-lymphoma.
Displaying page 1 of 4.
EudraCT Number: 2006-001888-40 | Sponsor Protocol Number: DEP NHL-P 001.A | Start Date*: 2006-07-24 | |||||||||||
Sponsor Name:Mundipharma Research Ltd. | |||||||||||||
Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg... | |||||||||||||
Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002241-22 | Sponsor Protocol Number: CA186-107 | Start Date*: 2014-12-26 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodg... | ||||||||||||||||||
Medical condition: Advanced Solid Tumors Advanced B-cell NHL | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003824-12 | Sponsor Protocol Number: ProRom | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Pilot phase II trial on safety and activity of secondary prophylaxis with Romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced throm-bocytopenia | |||||||||||||
Medical condition: chemotherapy-induced thrombocytopenia in patients affected by non-Hodgkin lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001666-32 | Sponsor Protocol Number: APM4083g | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA... | |||||||||||||
Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002141-37 | Sponsor Protocol Number: HOVON 80 NHL | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:HOVON foundation | |||||||||||||
Full Title: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-ce... | |||||||||||||
Medical condition: relapsed B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004908-37 | Sponsor Protocol Number: IRIS | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding... | |||||||||||||
Medical condition: indolent CD-20 positive lymphoma of conjunctiva | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015504-25 | Sponsor Protocol Number: GAO4753g | Start Date*: 2010-06-04 | |||||||||||
Sponsor Name:GENENTECH, Inc | |||||||||||||
Full Title: An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, ... | |||||||||||||
Medical condition: CD20+, indolent NHL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) ES (Completed) SE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000124-15 | Sponsor Protocol Number: TAS-2010 | Start Date*: 2011-06-22 | |||||||||||
Sponsor Name:Ergomed Clinical Research Limited | |||||||||||||
Full Title: An Open-Label, Multi-Center Phase I/IIa Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Oral Tasidotin HCL in Patients with Relapsed/Refractory Aggressive Non-... | |||||||||||||
Medical condition: aggressive non-Hodgkin's lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002406-31 | Sponsor Protocol Number: IPI-145-08 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Infinity Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma | |||||||||||||
Medical condition: Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) BE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003645-42 | Sponsor Protocol Number: CA209-140 | Start Date*: 2014-02-03 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05 | |||||||||||||
Medical condition: Lymphoma. Non-Hodgkin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002272-27 | Sponsor Protocol Number: DSHNHL2015-1 | Start Date*: 2017-04-06 | |||||||||||
Sponsor Name:Saarland University | |||||||||||||
Full Title: Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabin... | |||||||||||||
Medical condition: Patients with first relapse or progression of aggressive Non-Hodgkin’s Lymphoma who are not eligible neither for autologous nor allogeneic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Ongoing) NL (Ongoing) PL (Ongoing) AT (Ongoing) PT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000576-26 | Sponsor Protocol Number: BO29337 | Start Date*: 2014-11-04 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF GDC-0199 (ABT- 199) PLUS BENDAMUSTINE PLUS RITUXIMAB (BR) IN COMPARISON WITH BR ALONE OR GDC-0199 PLUS RITUXIMAB (R) IN PATIENTS W... | |||||||||||||
Medical condition: Relapsed and refractory follicular non-Hodgkins Lymphoma (R/R FL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) DE (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-003987-74 | Sponsor Protocol Number: 114-NH-302 | Start Date*: 2007-06-08 | |||||||||||
Sponsor Name:Biogen Idec Ltd. | |||||||||||||
Full Title: A Phase III, Open-Label, Multicenter, Single-Arm, Retreatment Study of Galiximab in Combination with Rituximab for Subjects with Relapsed, Follicular Non-Hodgkin’s Lymphoma who Previously Responded... | |||||||||||||
Medical condition: Relapsed, Follicular Non-Hodgkin’s Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) ES (Completed) AT (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) SK (Completed) SE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003621-28 | Sponsor Protocol Number: CA209-139 | Start Date*: 2014-02-03 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT... | |||||||||||||
Medical condition: Lymphoma. Non-Hodgkin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) SE (Completed) ES (Completed) IT (Completed) DE (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017269-49 | Sponsor Protocol Number: IC 2009-06 | Start Date*: 2010-02-08 | |||||||||||
Sponsor Name:INSTITUT CURIE | |||||||||||||
Full Title: Etude de phase II d’évaluation de la toxicité et de l’efficacité d’un traitement par Tacrolimus (Prograf®) chez des patients atteints d’un lymphome diffus à grandes cellules B ou T. | |||||||||||||
Medical condition: Lymphomes malins diffus à grandes cellules B ou T. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000434-47 | Sponsor Protocol Number: IM-T-hA20-08 | Start Date*: 2008-07-22 | ||||||||||||||||
Sponsor Name:Immunomedics, Inc. | ||||||||||||||||||
Full Title: A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia | ||||||||||||||||||
Medical condition: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001570-17 | Sponsor Protocol Number: LYMRIT-37-06 | Start Date*: 2015-09-14 | ||||||||||||||||
Sponsor Name:Nordic Nanovector ASA | ||||||||||||||||||
Full Title: A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin™) in patients with CD37-positive relapsed follicular lymphoma | ||||||||||||||||||
Medical condition: Relapsed CD37+ non-Hodgkin B-cell follicular lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) AT (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-005506-42 | Sponsor Protocol Number: NHL-HIV+ | Start Date*: 2007-10-19 | |||||||||||
Sponsor Name:OSPEDALE S. RAFFAELE | |||||||||||||
Full Title: HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT | |||||||||||||
Medical condition: HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005459-13 | Sponsor Protocol Number: IPI-145-19 | Start Date*: 2015-09-15 | |||||||||||
Sponsor Name:Infinity Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Two-arm, Phase 1b/2 Study of IPI-145 Administered in Combination with Rituximab or Obinutuzumab in Subjects with Previously Untreated CD20+ Follicular Lymphoma | |||||||||||||
Medical condition: Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) BE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002339-44 | Sponsor Protocol Number: IGM-2323-001 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:IGM Biosciences, Inc. | |||||||||||||
Full Title: A Phase 1/2 Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of IGM-2323 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphomas | |||||||||||||
Medical condition: Relapsed/Refractory (R/R) Non-Hodgkin lymphomas (NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) ES (Ongoing) IT (Ongoing) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.